Bright Green Corporation announced that it will move forward with its previously announced strategic arrangement and confirms its intention to exercise the call option on the total acquisition of the remaining issued and outstanding common stock of Alterola Biotech, a U.K.-based pharmaceutical company focused on developing cannabinoid and cannabinoid-like medicines and products. By exercising its option to purchase Alterola’s remaining issued and outstanding common stock over the coming months, Bright Green will complete the acquisition using Bright Green common stock.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BGXX:
- Bright Green Announces Decision to Complete Alterola Biotech Acquisition
- Bright Green refutes allegations made by Jerry Capussi, John Fikany
- Bright Green receives first funds from EB-5 Program
- Bright Green Announces the Receipt of Its First Funds from Its EB-5 Program
- Bright Green appoints McAuley as CEO